Table 3.
Optum and Truven stroke data for 1 year after atrial fibrillation (AF) diagnosis.
| Population for rates | Truven, n (%) | Optum, n (%) | Total, n (%) | Event rates (%) |
| All patients | 32,046,193 (50.63) | 31,249,927 (49.37) | 63,296,120 (100) | —a |
| Patients aged ≥18 years in 2016 with any diagnosis of AF during October 2015-September 2016 | 422,092 (32.79) | 865,072 (67.21) | 1,287,164 (100) | — |
| Patients aged ≥18 years in 2016 with any diagnosis of AF during October 2015-September 2016 and without a VHDb diagnosis during 1-year preindex | 355,811 (36.76) | 611,990 (63.24) | 967,801 (100) | 1.5 |
| Patients aged ≥18 years in 2016 with any diagnosis of AF during October 2015-September 2016 and without VHD diagnosis during 1-year preindex and with CHA2DS2‑VAScc ≥2 and no contraindications to OACd | 276,465 (33.87) | 539,775 (66.13) | 816,240 (100) | 84.3 |
| Patients aged ≥18 years in 2016 with any diagnosis of AF during October 2015-September 2016 and without VHD diagnosis during 1-year preindex and with CHA2DS2‑VASc ≥2 and no contraindications to OAC and were untreated | 179,441 (36.20) | 316,308 (63.80) | 495,749 (100) | 60.7 |
| Stroke rate | 11,530 (52.36) | 10491 (47.64) | 22,021 (100) | 4.4 |
| Death rate | 727 (55.1) | 593 (44.9) | 1,320 (100) | 5.99 |
aThe values are not events.
bVHD: valvular hear disease.
cCHA2DS2‑VASc: congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, stroke or transient ischemic attack, vascular disease, age 65 to 74 years, sex category.
dOAC: oral anticoagulation.